# OPTH · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** OPTH  
**Sources:** 30  
**Published:** 2026-08-05  
**Canonical:** https://app.k3vl4r.com/research/deep-research-opth-catalysts-narrative-risks-1540

---

# OPTH (Optimi Health Corp.) — Research Summary as of August 5, 2026

## Company Overview

Optimi Health Corp. (NASDAQ: OPTH / CSE: OPTI / FSE: 8BN) is a Canadian company focused on pharmaceutical-grade psychedelic compounds, including naturally derived psilocybin and ibogaine. The company operates GMP-certified production facilities in Canada and is positioning itself within the growing regulatory and clinical landscape for psychedelic-assisted therapies for mental health [[1]](https://marketchameleon.com/articles/b/2026/6/8/optimi-health-ibogaine-supply-regulatory-psychedelic-therapies)[[20]](https://ir.optimi.net/).

---

## Key Recent Catalysts (Last ~1–3 Months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-opth-catalysts-narrative-risks-1540 (free to sign up)._